⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 23, 2024HeliyonOpen Access

Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of ALI/ARDS patients with COVID-19

Ruiying Wang Junping Yin Jian Li Xueli Bai Hu Liu Mengyu Cheng Lei Wang Yuan Chen Shuang Wei Xiansheng Liu

View Full Paper

Ask AI

Bookmark

Share

Abstract

Sivelestat, a neutrophil elastase inhibitor, is postulated to mitigate acute lung injury in patients following emergency surgery. However, its efficacy in patients with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) induced by coronavirus disease 2019 (COVID-19) remains uncertain. This study aims to evaluate the pulmonary protective effects of sivelestat in COVID-19 patients with ALI/ARDS.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e5b27db6db64358754b527 https://doi.org/10.1016/j.heliyon.2024.e36337

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Neutrophil Elastase Inhibitor (Sivelestat) in the Treatment of Acute Respiratory Distress Syndrome Induced by COVID- 19: A Multicenter Retrospective Cohort Study2024
2The effectiveness of selective neutrophil elastase inhibitors (sivelestat) in acute lung injury or acute respiratory distress syndrome: A systematic review and meta-analysis of randomized controlled trialsMeta-Analysis · 2026 · 1 citations
3Sivelestat protects against acute lung injury by up-regulating angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas receptors2024 · 1 citations
4Efficacy Analysis and Prognostic Impact of Sivelestat Sodium in Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome2024 · 8 citations
5Efficacy and optimal timing of sivelestat in critically ill patients with COVID-19: a multicenter retrospective cohort studyCohort Study · 2026